Navigation Links
Cure Insight for DMD

According to the researcher Dr. Jacques P. Tremblay who is in the Human Genetics Department at Quebec City's Centre Hospitalier Universitaire de Québec (CHUQ) // and professor with Université Laval's Faculty of Medicine muscle cell transplant is one of the important alternatives to cure Duchenne muscular dystrophy. He and his team of researchers conducted the muscle cell transplant in young patients in 2004. The results were that eight out of the nine patients showed improvement. Duchenne muscular dystrophy is a progressive weakening and degeneration of the muscles, caused by a mutation in a gene coding for a protein called dystrophin.

This protein is absent in the muscles of people affected with the disorder. With the healthy muscle cells grafted by the team of researchers, a considerable proportion of patients' muscle fibers are now able to synthesize the missing protein. Analyses showed that between 4% and 26% of muscle cells in the cubic centimeter of treated muscle eventually produce the protein produced by the fusion of the donor cells. The results are published in the latest issue of the Journal of Neuropathology and Experimental Neurology. Dr. Tremblay's team is the first in the world to achieve this level of dystrophin expression in so many patients, and in such a high percentage of fibers.

Duchenne muscular dystrophy is a hereditary disease affecting one boy in 3,500. The first signs appear in childhood, between the ages of two and five. Its victims are confined to a wheelchair by their early teens. The disease progressively weakens all muscles, notably respiratory muscles, compromising life expectancy. Most sufferers die between the ages of 20 and 30. Today, there is no treatment--only rehabilitation, surgical procedures and prednisone to enhance patients' quality of life. New clinical trial: seeking ten patients Based on these results, professor Tremblay has received authorization to conduct a second round of clinical trials.
These new trials are supported financially by SOVAR, CellGene Inc., and Association Fran?aise contre les Myopathies. In this second trial, some 300 million donor cells will be transplanted into a complete muscle in the recipient's forearm. Patients' strength will be measured before their grafts, then three and six months after. This experiment will enable researchers to determine whether the transplant significantly increases the strength of the grafted muscle. Dr. Tremblay's team is seeking ten patients over the age of 18 who suffer from Duchenne or Becker muscular dystrophy. Patients are asked to talk to their neurologists, who can help them contact the researchers. Dr. Tremblay received the 2005 Sirius research award for his work on Duchenne muscular dystrophy. More recently, the Royal College of Physicians and Surgeons of Canada and the Canadian Society for Clinical Investigation together awarded him the Henry-Friesen Award honoring a distinguished scientist whose biomedical research is recognizable on the international stage as novel and original and of the highest caliber. The multidisciplinary CHUQ team headed by Dr. Jacques P. Tremblay includes Dr. Daniel Skuk, Dr. Michel Sylvain, Dr. Jack Puymirat, Dr. Jean-Pierre Bouchard, Dr. Louise Deschènes, Dr. Hélène Senay, Dr. Jean-Guy Lachance, Dr. Raynald Roy, and Dr. Pierre Dalens.

'"/>




Related medicine news :

1. fMRI Offers Insight Into An Infants Brain
2. New Insight To The Role Of Peptide Signals
3. New Insight Gained For Allergic Reactions
4. Insight for Hot Flashes In Postmenopausal Women
5. New Insight In Periodontal Disease In Postmenopausal Women
6. Researchers Bring New Insight To Asthma And SABA Fills
7. Study Unveils New Insight To The Madness Of King George III
8. Study Offers Insights Into Treatment Of Rheumatoid Arthritis
9. Reindeer Provide Valuable Insights Into Sleep Disorders
10. Insight Into The Risky Health Decisions On Bird Flu
11. Insights Into Lead Pollution
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/4/2016)... New York, NY (PRWEB) , ... May 04, ... ... nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving ... patient services – is set to return to the esteemed Quaker Ridge Golf ...
(Date:5/4/2016)... ... May 04, 2016 , ... The ... research and development of DRACO broad-spectrum antiviral therapeutics. DRACOs have proven effective against ... on May 3, 2016 at http://igg.me/at/EndTheVirus and runs for 60 days, ...
(Date:5/4/2016)... ... May 04, 2016 , ... IsoComforter, ... the introduction of the innovative newly improved Iso-Hip Wrap. The newly designed ... plush design enhances comfort and enables the patient to enjoy the benefits of ...
(Date:5/4/2016)... New York, NY (PRWEB) , ... May 04, ... ... country’s leading private owners, developers and operators of commercial real estate proudly announced ... its 2015 Heart Health initiative. Team members portfolio-wide will continue Olshan Properties’ ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... The ... Day to recognize chaplains for their valuable support to patients and their families, and ... May 10. , To mark Spiritual Care Day, SCA has sent “Thank You Chaplain” ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... , May 4, 2016 According ... Research entitled "Brain Computer Interface Market - Global Industry Analysis, ... global brain computer interface (BCI) market  is expected to ... market is estimated to expand at a CAGR of ... 2024. A BCI device provides collaboration between ...
(Date:5/4/2016)... an upgrade. There are many medical recorders on the market but none like this. ... HD  offers unparalleled connectivity and functionality.  Ampronix  is a renowned authorized reseller of the ... Photo - http://photos.prnewswire.com/prnh/20160503/363416 ... ... ...
(Date:5/4/2016)... Israel , May 4, 2016 ... today that BiondVax,s CEO, Dr. Ron Babecoff , will ... New York City . On Thursday, ... Pioneers 2016, a conference presented by Joseph Gunner ... The BiondVax presentation that Dr. Babecoff will be ...
Breaking Medicine Technology: